# Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults

> **NCT01155037** · PHASE2 · COMPLETED · sponsor: **Oswaldo Cruz Foundation** · enrollment: 450 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** Adjuvanted vaccine against H1N1 influenza virus (GSK)
- **BIOLOGICAL:** Adjuvanted vaccine against H1N1 influenza virus (GSK)
- **BIOLOGICAL:** Adjuvanted vaccine against H1N1 influenza virus (GSK)

## Key facts

- **NCT ID:** NCT01155037
- **Lead sponsor:** Oswaldo Cruz Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-03
- **Final completion:** 2012-04
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2018-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01155037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01155037, "Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01155037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*